EXAMINE

ENABLE

ELEVATE

Building a strong, sustainable healthcare industry

Life sciences

With a focus on innovation to support a healthier Australia and avoid future crises, life sciences continues to be an increasing focus and a critical development and investment area in the Australian economy. Funding, manufacturing and supply chain challenges remain a key concern to secure access to essential medicines and devices. Domestic and overseas stakeholders, however, are showing great interest in the Australian market.

There is opportunity for Australia's strong medical research base to be leveraged to improve product commercialisation. Working with healthcare industry participants, the life sciences sector can plays a critical role in a broader health ecosystem that embraces transformation and growth. We are helping the life sciences industry address those challenges to deliver innovative and accessible healthcare solutions to the market – both in Australia, and globally.

MEET AN EXPERT

Support across the whole life cycle

Our multi-disciplinary team works with domestic and international biotechnology, pharmaceutical, medical device, digital and technology companies, investors and medical research institutes. We support our clients across the entire life cycle – from conception to commercialisation and beyond.

With many of our team members dual-qualified in a sciences discipline, we understand the complex legal and regulatory landscape life sciences companies face – alongside the technology and science.


Case studies

Short image

Grey Innovation

Supporting with the implementation of its emergency ventilator program, undertaken in response to the COVID-19 emergency situation. The program, known as the notus Emergency Invasive Ventilator Program, secured financial support from the Federal and Victorian Governments and the Advanced Manufacturing Growth Centre.

Short image

Brandon Capital

Acted on the establishment of the Medical Research Commercialisation Fund (now Brandon BioCatalyst), Australia’s largest life sciences venture capital fund. Continuing role as advisors to Brandon on ongoing investments and exits, including Venture Capital Deal of the Year for investment in Longas Technologies.

Short image

Arrotex Holdings

Advised on the acquisition and merger of Arrow Pharmaceuticals and Apotex's Australian subsidiaries and business to form Arrotex Holdings Pty Ltd. The merger made Arrotex Australia's largest generic pharmaceutical and private label OTC business with over 50% market share of the Australian generic pharmacy market.

Short image

CDH Investments and China Grand Pharmaceutical and Healthcare Holdings Limited

On the successful A$1.9 billion joint public takeover bid of Sirtex Medical (ASX).

Short image

Viatris (previously Mylan)

Represented in asserting three patents relating to fenofibrate (a drug used to treat diabetes-related conditions) against Sun Pharma (formerly Ranbaxy) in the Federal Court.

Short image

Ginkgo Bioworks

Advised in relation to its entry into a technical development agreement (Development Agreement) with ASX-listed Microba Life Sciences (ASX:MAP); and its participation as a cornerstone investor in Microba Life Sciences’ IPO.

eyJhbGciOiJIUzI1NiIsInR5cCI6IkpXVCJ9.eyJuYW1laWQiOiJkMjMwY2Y4Yi0wZWExLTQwMmItOWM1OS00MGU4ZDM1YmE3OWIiLCJyb2xlIjoiQXBpVXNlciIsIm5iZiI6MTY2NDQ2OTk5MSwiZXhwIjoxNjY0NDcxMTkxLCJpYXQiOjE2NjQ0Njk5OTEsImlzcyI6Imh0dHBzOi8vd3d3Lm1pbnRlcmVsbGlzb24uY29tL2hlYWx0aC9saWZlLXNjaWVuY2VzIiwiYXVkIjoiaHR0cHM6Ly93d3cubWludGVyZWxsaXNvbi5jb20vaGVhbHRoL2xpZmUtc2NpZW5jZXMifQ.1lgIejoAFmOEHeerQ_f-tKylRlR7mK5vgmmp-ahflaE
https://www.minterellison.com/health/life-sciences

Knowledge and expertise

Our depth of life sciences experience covers all aspects of advising on strategic M&A, capital raisings and IPOs, foreign investment, corporate governance, commercial transactions, commercialisation strategies, regulatory issues, intellectual property, patent and other litigation, competition law, employment issues, tax (including R&D tax concession, transfer pricing and ATO audits), insurance and management of claims arising from adverse outcomes, regulation of pharmaceuticals and medical devices including Therapeutic Goods Act requirements, compliance with industry standards and codes (including MA and MTAA), and reimbursement issues relating to the Pharmaceutical Benefits Scheme.